Source: Andrew A. Moshfeghi, MD, MBA
March 06, 2021
1 min watch
Save

VIDEO: Tyrosine kinase inhibitor implant performs well in phase 1 study for wet AMD

Source: Andrew A. Moshfeghi, MD, MBA
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Andrew A. Moshfeghi, MD, MBA, discusses results from a phase 1 study of an intravitreal hydrogel axitinib implant for wet AMD he recently presented at the virtual Angiogenesis, Exudation, and Degeneration meeting.

OTX-TKI from Ocular Therapeutix showed good safety, tolerability and efficacy.